{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T06:10:40Z","timestamp":1788588640965,"version":"build-2803163510"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T00:00:00Z","timestamp":1758672000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012317","name":"UCLH Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012317","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuromuscular Disorders"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.nmd.2025.106222","type":"journal-article","created":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T04:00:52Z","timestamp":1758772852000},"page":"106222","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Long term safety and efficacy of lamotrigine in patients with non-dystrophic myotonia, a single-centre prospective study"],"prefix":"10.1016","volume":"56-57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3052-9952","authenticated-orcid":false,"given":"Murva","family":"Asad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iwona","family":"Skorupinska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"James","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dipa","family":"Jayaseelan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael G","family":"Hanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinojini","family":"Vivekanandam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nmd.2025.106222_bib0001","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.nmd.2023.01.007","article-title":"Prevalence of genetically confirmed skeletal muscle channelopathies in the era of next generation sequencing","volume":"33","author":"Vivekanandam","year":"2023","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2025.106222_bib0002","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1136\/jmg.35.4.293","article-title":"Myotonia congenita in northern Finland: an epidemiological and genetic study","volume":"35","author":"Baumann","year":"1998","journal-title":"J Med Genet"},{"issue":"12","key":"10.1016\/j.nmd.2025.106222_bib0003","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1038\/sj.ejhg.5200736","article-title":"Spectrum of CLCN1 mutations in patients with myotonia congenita in Northern Scandinavia","volume":"9","author":"Sun","year":"2002","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.nmd.2025.106222_bib0004","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1093\/brain\/awp294","article-title":"The non-dystrophic myotonias: molecular pathogenesis, diagnosis and treatment","volume":"133","author":"Matthews","year":"2010","journal-title":"Brain"},{"key":"10.1016\/j.nmd.2025.106222_bib0005","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1007\/s00415-009-5049-y","article-title":"Health status in non-dystrophic myotonias: close relation with pain and fatigue","volume":"256","author":"Trip","year":"2009","journal-title":"J Neurol"},{"key":"10.1016\/j.nmd.2025.106222_bib0006","doi-asserted-by":"crossref","first-page":"857","DOI":"10.3390\/ijms24010857","article-title":"Blockers of skeletal muscle Nav1.4 channels: from therapy of myotonic syndrome to molecular determinants of pharmacological action and back","volume":"24","author":"De Bellis","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.nmd.2025.106222_bib0007","article-title":"Drug treatment for myotonia","volume":"4","author":"Spillane","year":"2025","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.nmd.2025.106222_bib0008","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.nmd.2021.06.010","article-title":"Efficacy and safety of mexiletine in non-dystrophic myotonias: a randomised, double-blind, placebo-controlled, cross-over study","volume":"31","author":"Vicart","year":"2021","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2025.106222_bib0009","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1001\/jama.2018.18020","article-title":"Effect of mexiletine on muscle stiffness in patients with nondystrophic myotonia evaluated using aggregated n-of-1 trials","volume":"320","author":"Stunnenberg","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.nmd.2025.106222_bib0010","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1001\/jama.2012.12607","article-title":"Mexiletine for symptoms and signs of myotonia in nondystrophic myotonia: a randomized controlled trial","volume":"308","author":"Statland","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.nmd.2025.106222_bib0011","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.00300","article-title":"Long-term safety and usefulness of mexiletine in a large cohort of patients affected by non-dystrophic myotonias","volume":"11","author":"Modoni","year":"2020","journal-title":"Front Neurol"},{"key":"10.1016\/j.nmd.2025.106222_bib0012","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1001\/jamaneurol.2015.2338","article-title":"Long-term safety and efficacy of mexiletine for patients with skeletal muscle channelopathies","volume":"72","author":"Suetterlin","year":"2015","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.nmd.2025.106222_bib0013","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1093\/brain\/awx192","article-title":"The antimyotonic effect of lamotrigine in non-dystrophic myotonias: a double-blind randomized study","volume":"140","author":"Andersen","year":"2017","journal-title":"Brain"},{"key":"10.1016\/j.nmd.2025.106222_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/S1474-4422(24)00320-X","article-title":"Mexiletine versus lamotrigine in non-dystrophic myotonias: a randomised, double-blind, head-to-head, crossover, non-inferiority, phase 3 trial","volume":"23","author":"Vivekanandam","year":"2024","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.nmd.2025.106222_bib0015","article-title":"Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child","volume":"2023","author":"Bromley","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.nmd.2025.106222_bib0016","article-title":"NaMuscla\u00ae Summary of Product Characteristics","year":"2025"},{"key":"10.1016\/j.nmd.2025.106222_bib0017","unstructured":"Lamictal. Full prescribing information (last revised october 2020). GlaxoSmithKline, Research Triangle Park, NC 27709, USA. Available from https:\/\/gskpro.com\/content\/dam\/global\/hcpportal\/en_US\/Prescribing_Information\/Lamictal\/pdf\/LAMICTAL-PI-MG.PDF [Accessed 10th July 2025]."},{"issue":"3","key":"10.1016\/j.nmd.2025.106222_bib0018","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/j.1365-2125.2008.03250.x","article-title":"Lamotrigine does not prolong QTc in a thorough QT\/QTc study in healthy subjects","volume":"66","author":"Dixon","year":"2008","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.nmd.2025.106222_bib0019","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1111\/j.1365-2125.2010.03855.x","article-title":"Effect of lamotrigine on the PR interval in healthy subjects","volume":"71","author":"Dixon","year":"2011","journal-title":"Br J Clin Pharmacol"},{"issue":"9","key":"10.1016\/j.nmd.2025.106222_bib0020","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1111\/epi.17339","article-title":"Cardiac morbidity and mortality associated with the use of lamotrigine","volume":"63","author":"Christensen","year":"2022","journal-title":"Epilepsia"},{"issue":"1","key":"10.1016\/j.nmd.2025.106222_bib0021","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000213643","article-title":"Risk of ventricular arrhythmia and sudden cardiac arrest among older patients using lamotrigine for epilepsy","volume":"105","author":"Ho","year":"2025","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2025.106222_bib0022","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/epi4.12475","article-title":"FDA safety warning on the cardiac effects of lamotrigine: an advisory from the Ad Hoc ILAE\/AES Task Force","volume":"6","author":"French","year":"2021","journal-title":"Epilepsia Open"},{"key":"10.1016\/j.nmd.2025.106222_bib0023","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.nmd.2005.07.002","article-title":"Quantification of mobility impairment and self-assessment of stiffness in patients with myotonia congenita by the physiotherapist","volume":"15","author":"Hammar\u00e9n","year":"2005","journal-title":"Neuromuscul Disord"},{"issue":"2\u20133","key":"10.1016\/j.nmd.2025.106222_bib0024","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.eplepsyres.2010.10.006","article-title":"Association study of lamotrigine-induced cutaneous adverse reactions and HLA-B*1502 in a Han Chinese population","volume":"92","author":"An","year":"2010","journal-title":"Epilepsy Res"}],"container-title":["Neuromuscular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896625009496?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896625009496?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T14:37:54Z","timestamp":1766068674000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960896625009496"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":24,"alternative-id":["S0960896625009496"],"URL":"https:\/\/doi.org\/10.1016\/j.nmd.2025.106222","relation":{},"ISSN":["0960-8966"],"issn-type":[{"value":"0960-8966","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long term safety and efficacy of lamotrigine in patients with non-dystrophic myotonia, a single-centre prospective study","name":"articletitle","label":"Article Title"},{"value":"Neuromuscular Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nmd.2025.106222","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106222"}}